Discontinued — last reported Q4 '18
This increase may warrant attention — for this metric, lower values are generally preferred.
Frequent or large impairment charges signal poor past investment decisions or deteriorating market conditions for specific business units.
These are non-cash charges recorded when the carrying value of an asset exceeds its fair market value. They represent a...
Peers in the pharmaceutical industry often record these following failed clinical trials or acquisition integration issues.
cf_impairment_charges| Q2 '21 | Q2 '22 | Q2 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Value | $14.00M | $610.00M | $426.00M | $185.00M | $194.00M | $0.00 | $26.00M | $30.00M | $0.00 | $93.00M |
| QoQ Change | — | >999% | -30.2% | -56.6% | +4.9% | -100.0% | — | +15.4% | -100.0% | — |
| YoY Change | — | >999% | -30.2% | — | -54.5% | — | — | -83.8% | -100.0% | — |
We use cookies for analytics. See our Privacy and Cookie Policy.